The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2015 | HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, provides a summary of the progression-free survival results of the phase 3 HELIOS trial, which evaluated ibrutinib in combination with bendamustine and rituximab for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
